Drugging RNA–Protein Complexes with Small Molecules to Enable RNA Splice Modulation & Degradation
- REM-422 is being developed by Remix Therapeutics for the treatment of ACC and AML/HRMDS
- REMaster™ platform identifies compounds that address undruggable high unmet medical need targets
- Next generation Remix drug discovery programs are enabled by a suite of biophysical assays and expand the scope of pharmacologically tractable splice modulator modalities